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Abstract
Background:  There is a considerable body of evidence on the effectiveness of specific
interventions in individuals who wish to quit smoking. However, there are no large-scale studies
testing the whole range of interventions currently recommended for helping people to give up
smoking; specifically those interventions that include motivational interviews for individuals who
are not interested in quitting smoking in the immediate to short term. Furthermore, many of the
published studies were undertaken in specialized units or by a small group of motivated primary
care centres.
The objective of the study is to evaluate the effectiveness of a stepped smoking cessation
intervention based on a trans-theoretical model of change, applied to an extensive group of Primary
Care Centres (PCC).
Methods/Design: Cluster randomised clinical trial. Unit of randomization: basic unit of care
consisting of a family physician and a nurse, both of whom care for the same population (aprox.
2000 people). Intention to treat analysis.
Study population: Smokers (n = 3024) aged 14 to 75 years consulting for any reason to PCC and
who provided written informed consent to participate in the trial.
Intervention: 6-month implementation of recommendations of a Clinical Practice Guideline which
includes brief motivational interviews for smokers at the precontemplation – contemplation stage,
brief intervention for smokers in preparation-action who do not want help, intensive intervention
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with pharmacotherapy for smokers in preparation-action who want help, and reinforcing
intervention in the maintenance stage.
Control group: usual care.
Outcome measures: Self-reported abstinence confirmed by exhaled air carbon monoxide
concentration of ≤ 10 parts per million. Points of assessment: end of intervention period and 1 and
2 years post-intervention; continuous abstinence rate for 1 year; change in smoking cessation stage;
health status measured by SF-36.
Discussion: The application of a stepped intervention based on the stages of a change model is
possible under real and diverse clinical practice conditions, and improves the smoking cessation
success rate in smokers, besides of their intention or not to give up smoking at baseline.
Trial Registration: Clinical Trials.gov Identifier: NCT00125905
Background
The data from the 50-year follow-up study involving Brit-
ish male doctors showed that one in two regular smokers
of cigarettes die as a result of tobacco-related disease. The
latest estimations showed that in Spain in 2001 there were
54,233 deaths attributable to tobacco consumption [1].
The data of the National Health Survey [Encuesta Nacional
de Salud] of 2006 showed that 29,9% of the adult Spanish
population smoked [2], with a clear tendency towards a
decrease in males and an increase in females.
Primary care can play a key role in the control of tobacco
consumption. The data from our country show that in
many zones more than 75% of the population attend an
outpatient consultation in the local Primary-Care Centre
(PCC) at least once a year, and the average number of vis-
its varies between 5 and 6 (data from the primary-care
database of 2001; Sistema de Información de Atención
Primaria, 2001). Spain has an almost universal coverage
of the population by a public health system in which pri-
mary care is the first point of contact. This provides a
unique opportunity for intervention, and therefore pre-
vention, in a large number of subjects on many occasions
even before chronic or severe diseases have begun. Fur-
thermore, surveys as those cited above showed that more
than 60% of smokers had a desire to quit smoking, and
the majority of these individuals have at some time or
other made an attempt to achieve this.
In the past few years, several national and international
clinical practical guidelines have been developed with rec-
ommendations to intervene on the consumption of
tobacco, based on help provided at health centers, both at
primary and specialist care levels.
Since 1996, various clinical guidelines integrating all the
evidence available from existing clinical research have
been published in different countries. Most of them were
from anglosaxon countries (mainly the USA, UK and Aus-
tralia). For example, the guidelines from the US Public
Health services published in 2000 (recently updated)[3]
were based on approximately 6000 original articles and
abstracts of congresses written in English and published
between 1977 and 1999. More than 50 meta-analysis
were carried out and became the basis for the recommen-
dations developed by a panel of 18 experts. Following
this, there was an external revision process by another
group of 70 experts [4].
The guidelines from the United Kingdom originated from
the meta-analysis derived from the American guidelines
and from the Cochrane international collaboration
reviews [5]. Furthermore, in the year 2000, appeared the
First European Directives on the Treatment of Tobacco
Dependence within the European Cooperative Project of
the World Health Organization.
Some of the recommendations of these guidelines have
been based on a large number of clinical trials and studies
of intervention. However, in other cases, there has been
weak evidence and the recommendations have been
based on the consensus opinions of experts.
Examples of intervention from the primary-care perspec-
tive for which there has been grade A evidence (based on
many high quality clinical trials containing consistent
results) are:
￿ Primary health care teams should ensure that their
records concerning which of their patients smoke are kept
up to date [A]
￿ GPs should advise current smokers to stop during rou-
tine consultations at least once a year, offer a prescription
for Nicotine Replacement Therapy (NRT), record the
response to that advice, and arrange follow up where
appropriate. [A]
￿ At the beginning of the study, and even now, the level of
evidence for some key recommendation were still C andBMC Public Health 2009, 9:48 http://www.biomedcentral.com/1471-2458/9/48
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mostly derived from published guidelines (recommenda-
tions based on consensus). These include:
▪ The role of motivational interviewing in accelerating
changes in the process of smoking cessation.
▪ The role of the primary care professionals in performing
more intensive interventions.
▪ The role of primary care nurses in motivating and help-
ing patients to quit smoking.
▪ The use in primary care of non-nicotine based pharma-
ceutical products such as bupropion, an atypical antide-
pressant considered in the guidelines as a first-line drug.
At the start of this study there was only limited experience
of its use in primary care.
There is only partial evidence for several of these recom-
mendations. For example, in the case of motivational
interviewing [6,7], the study by Butler et al showed out-
comes less positive than those expected [8], and subse-
quent reviews showed some inconsistencies [9-12].
Motivational interviewing is difficult to evaluate because
of its intrinsic nature (variability and adaptation to char-
acteristics both from patients and health professionals,
and from the interaction between them in each clinical
encounter) and also due to the difficulty of finding useful
and appropiate measures of success. Another important
aspect to consider is the fact that motivational interview-
ing requires a change in the way health professionals
interact with patients.
The Cochrane review of smoking cessation interventions
conducted by nurses showed that there can lead to poten-
tial benefits and that there is fair evidence of their effec-
tiveness. Again there are few studies in primary care and
some of these studies show that the interventions carried
out during preventive check-ups are less effective [13].
The use of bupropion was not yet protocolised in primary
care, although the Cochrane review does recommend it as
a first-line drug. [14].
One of the conceptual models that has been most exten-
sively used to explain the process of change in addictive
behaviour is that developed by Prochaska and DiCle-
mente in 1982. These researchers defined a series of suc-
cessive stages each of which require different types of
interventions [15,16]. The use of this model is frequently
linked to the motivational interviewing strategies
described earlier. It is recommended that the interven-
tions applied in primary care must be orientated towards
achieving advances in this addiction process, and not only
to giving up smoking. As such, stage change can be used
as an intermediate measure of the effectiveness of the
interventions. The majority of the clinical guidelines used
in our Spanish environment include an assessment of the
stage of smoking cessation in which the individual
smoker is currently located [17].
Although the amount of research about smoking inter-
vention is impressive, many of the studies have been con-
ducted in highly selected populations of smokers and
there have not been any studies that have evaluated all the
range of interventions developed, applying them in a
stepped manner to non-selected smokers who consult pri-
mary care centers for other reasons. Interventions include
brief motivational interviews for smokers at the precon-
templation – contemplation stage, brief intervention for
smokers in preparation-action who do not want help,
intensive intervention with pharmacotherapy for smokers
in preparation-action who want help, and reinforcing
intervention in the maintenance stage.
In Spain, the first studies date from the end of the 1980s
when a group of primary care professionals in Barcelona
(including two of the researchers of this study; Cabezas C
and Martin C) replicated the effectiveness of the brief
intervention study of Russell et al in the UK in 1979
[18,19].
Since then, and extending their field of study to include
the primary care environment, the same research team
have evaluated the effectiveness of nicotine chewing gum
and nurse-based advice [20]. Subsequent studies by
Quilez, Salvador, Comas, Torrecilla, etc. [21-24] have
found results consistent with those of the international
studies. Some of these studies had also been carried out in
primary care centers, but by health-care professionals spe-
cially trained in this area.
Among the published studies there are at least two types
of interventions which have been widely evaluated: the
Doctors Helping Smokers (DHS) Program proposed by
Solberg [25,26], adapted to Spain by Solberg and Nebot
and applied in Spain by Martin, Casas, Cordoba and Bal-
lvé (members of the ISTAPS research group) and the Pro-
gram to Quit Tobacco by Grandes and Cortada [27]. The
DHS program is based on the proposals of the first guide-
lines of American National Cancer Institute at the end of
the 1980s which are easily applied in primary care. The
main limitations of the program arose from the very brief
intervention proposed and from the lack of a formal eval-
uation of its effectiveness in Spain. [28].
The study by Grandes et al. is a quasi-experimental study
which included a large number of smokers with an evi-
dence-based strategy. However, it does not include current
recommended strategies such as motivational interview-
ing, more intensive help (the authors evaluated a thera-
peutic plan with three visits and one telephone call), norBMC Public Health 2009, 9:48 http://www.biomedcentral.com/1471-2458/9/48
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the use of other drugs (other substitutes for nicotine than
patches and bupropion) [29].
Hence, when faced with reviewing the evidence and devel-
oping a clinical guideline for Spain, the authors of the
present project found that there was no clear evidence
either for some of the proposed recommendations, or for
the overall strategy. This led to the current proposition for
a study identifying this evidence. In order to put into prac-
tice the intervention proposed health professionals must
be trained. Some parts of the intervention (those related
with motivational interviewing) require not only the
development of skills but also a change in the way health
professionals interact with patients. For this reason, and
in order to minimize contamination, the unit of randomi-
zation and analysis was the basic care unit consisting of a
physician and nurse who take care of the same list of
patients, both of whom received a 20-hours training
course at the beginning of the study.
The opportunity to detect and follow-up a cohort of per-
sons from before quitting smoking to more than 1 years
post-quitting would facilitate the study of variation in the
overall health-related quality of life produced as a result of
the process of quitting smoking, and also provide a meas-
ure of the impact on health status. The studies published
about this theme are comparisons of the perceptions of
health-related quality of life in smokers and ex-smokers
[30]. Serial data in clinically relevant moments of the
smoking cessation process would highlight the times and
the scale at which the most relevant changes in the health-
related quality of life are produced.
The SF-36 is a multi-purpose, short-form health survey
validated in Spain by Alonso et al [31]. It consists of 36
questions measured in an ordinal scale. It can be self-
administered or used in personal or telephone interviews.
This yields a profile of functional health and well-being
score, as well as psychometrically-based physical and
mental health summary measures The profile considers 8
scales: Physical Functioning, Role-Physical, Bodily Pain,
General Health, Vitality, Social Functioning, Role-Emo-
tional, Mental Health and two summary measures: Physi-
cal Component Summary (PCS) and Mental Component
Summary (MCS).
Additionally, one of the items evaluates the change in
health status over the previous year. The items detect not
only positive but also negative health status. The SF-36 is
sufficiently sensitive to changes when compared to other
questionnaires such as the Nothingham or the Sickness
Impact Profile that have been especially useful in clinical
trials up until now. One version of the SF36 that measures
the health perception over the precedent week, known as
the acute version, enables the changes to be evaluated
within the interval of time envisaged in the present study.
Objectives
Objectives
￿ To evaluate the effectiveness of a stepped smoking cessa-
tion intervention based on a transtheoretical model of
change that uses the pharmacological and non-pharmaco-
logical methods proposed by evidence based Clinical
Practice Guidelines for smoking cessation in primary care
centres. The effectiveness will be measured at patient level
as the continuous abstinence for at least one year, adjust-
ing for the effect of cluster randomization.
￿ To assess the health-related quality of life change in rela-
tion to the smoking cessation process.
Methods/design
Study design
Cluster randomized clinical trial
Setting
Primary Care Centers (PCC).
Study population
All the basic care units of health professionals belonging
to the Spanish Preventive Services and Health Promotion
Research Network (redIAPP) that expressed their inten-
tion to participate were included (n = 121). These health
professionals worked in 82 primary care centres in 11 dif-
ferent regions of Spain.
Between the years 2003 and 2004, individuals aged
between 14 and 75 years old who attended the primay
care center for any reason, who answered positively to the
question "Do you smoke?" and who provided informed
consent to participation in the present study, were
recruited. People suffering from terminal illnesses, severe
psychiatric disorders, addiction to other psychoactive sub-
stances, or those unwilling to participate in the study were
excluded. The recruitement continued for 12 months.
Unit of Randomization: Basic care unit. The system of ran-
domization was centralized and computer generated.
Description of the intervention
The intervention consisted in the application of the rec-
ommendations of a evidence-based practical clinical
guideline developed over 6 months by a team from the
research group. The guideline was prepared for the Pri-
mary Care Division of the Catalan Institute of Health and
which has not yet been distributed.
The basic steps in the intervention are:
1. All individuals accessing the PCC, once the motivating
problem of the clinical visit had been resolved, were asked
about tobacco consumption, their willingness to quit
smoking (the stage of change according to the modelBMC Public Health 2009, 9:48 http://www.biomedcentral.com/1471-2458/9/48
Page 5 of 11
(page number not for citation purposes)
defined by Prochaska and DiClemente) and their need for
specific help in quitting smoking.
2. Individuals in the pre-contemplation or the contempla-
tion stage were administered a brief motivational interview
based on the Rollnick and Butler [8] model and were pro-
vided with a leaflet containing motivational information.
3. Individuals in the preparation or action stage who pre-
ferred the option of no specific help, received a minimal
intervention which included brief advice, a leaflet con-
taining practical information on how to quit, an offer/pre-
scription of nicotine substitute if their nicotine
dependence was medium or high, and one follow-up clin-
ical visit or telephone call.
4. Individuals in the preparation or the action stage who
requested specific help, received an intensive intervention
comprising of 9 scheduled follow-up visits over 1 year
wich included behavioral intervention, and use of phar-
macological agents (substitutes for nicotine or bupropion
according to the characteristics of the subject and their
previous experiences as regard quitting smoking). They
were provided with a leaflet of practical information on
how to quit and another with specif advice on how to use
the pharmacological treatment.
5. Individuals in the maintenance stage were provided
with reinforcement advice.
All the individuals included in the intervention group had
the intervention applied in a period of 6-months after
their inclusion in the study. In the case of scheduled visits
for smoking cessation and non-attendance, the motive
was sought out. The successive interventions were adapted
to each person's evolution according to the Prochaska and
DiClemente's Stages of Change Model.
All the health care professionals in the intervention group
attended a 20 hours course that uses techniques such as
role playing, as well as a training session in the practical
aspects of the protocol.
Control: The patients in the control group received the
usual care in the PCC.
Outcome measures
Self reported abstinence confirmed by a breath carbon
monoxide concentration of 10 parts per millions or less,
calculating point prevalence at the end of intervention,
then at 1 and 2 years after the beginning of intervention,
and continuous abstinence rate for 1 year.
The measurement of breath carbon monoxide was carried
out by trained health professionals using Bedfont Scientific
Ltd. Smokerlyzers following a pre-established protocol.
Other outcome measures:
￿ Change of stage in the Prochaska and DiClemente's
Stages of Change Model.
￿ Health-related quality-of-life (HRQoL): Medical Out-
comes Study 36-Item Short-Form Health Survey (SF-36)
acute version (1-week recall period) in persons who quit
smoking at baseline and at 2, 4, 12, 26, 52 and 104 weeks
after having quit smoking.
Data collection
An ad-hoc questionnaire that included data relating to:
￿ Socio-demographic characteristics (age, gender, educa-
tional level, social class according to the classification of
the UK Registrar General's social classification (RGSC)).
￿ Anthropometric data (weight, height, blood pressure).
￿ Characteristics of individual's tobacco consumption
(daily consumption in cigarettes/day, years of smoking,
age at the start, time before first cigarette of the day, nico-
tine dependence measured by the Fagerström test, motiva-
tion level measured by the Richmond test), help sought to
quit smoking, perceived support or lack from family,
friends and co-workers.
￿ Variables related to the Prochaska – Diclemente tran-
stheoretical model of change: stages, self-change proc-
esses, self-efficacy and decisional balance.
￿ Readiness and willingness to quit (perception of impor-
tance, confidence and preparation to quit; Richmond test).
￿ Morbidity (whether or not related to tobacco consump-
tion) and intensity of use of primary care services.
￿ Alcohol consumption, use of other recreational drugs
and physical exercise.
￿ Variables related to the smoking intervention provided:
▪ Professional who undertook the intervention (physician
or nurse)
▪ Pharmacological treatment used: type, timetable, side
effects
￿ As regards people who managed to give-up smoking:
▪ Ratings of tobacco abstinence symptoms (urges to
smoke, irritability/frustration/anger, anxiousness, diffi-
culty concentrating, restlessness, hunger, impatient, crav-
ing for cigarette/nicotine, drowsiness, depression/feeling
blue, and desire for sweets)BMC Public Health 2009, 9:48 http://www.biomedcentral.com/1471-2458/9/48
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▪ Scale of anxiety and depression (Goldberg test)
▪ MOS-SF-36
This questionnaire was divided in two parts (one clinical
and another non clinical) and administered at baseline, at
the end of intervention (6 months), and after one and two
years from the start. The morbidity and use of services data
were obtained by health professionals from clinical
records.
In people who gave-up smoking, the specific questions
related to the quitting process were assessed again in extra
interviews at week 2, and at 1, 2 and 4 months after quit-
ting smoking.
The clinical part of the questionnaire was administered in
primary care centers by the health professional involved
in the study. The non clinical part was administered by
phone by especially trained interviewers who were
blinded to the patient group assignment.
Follow-up period
Two years from the start of the intervention.
Figures 1 and 2 shows: Time-line of the ISTAPS project
and ALGORITHM OF THE STUDY.
Sample size calculation
Based on different assumptions
￿ Power 80%, alpha 0.05, potential study withdrawal
(15%).
￿ A difference of 5% between the success rate of the inter-
vention (10%) and control group (5%) -> a sample size of
499 in every group was needed.
￿ A difference of 20% between the success rate of the inter-
vention (30%) and control group (10%) for people in the
preparation stage -> a sample size of 110 in the prepara-
tion stage in every group was needed. Previous studies in
Spain (Grandes et al. 2001) showed that approximately
16% of smokers seen in primary care centres were in the
preparation stage, and thus, it was necessary to include
687 smokers in every group to obtain 110 in the prepara-
tion stage. As this number is greater than the 499 stated
previously, this number is used for input in adjusting for
the design effect.
￿ It was considered feasible that each basic care unit
would include some 25 individuals in the study.
￿ The intracluster correlation coefficients (ICC) for out-
come variables in cluster randomization clinical trials on
guidelines implementation strategies in primary care are
generally below 0,05 [32]. This ICC translates into a clus-
ter size of 25 in a design effect of 2.2.
As such, the definitive sample size for the study would be
3024 patients (1512 in each group) corresponding to 121
basic health-care units (61 in each group, intervention
and control).
The sample size calculations were performed with the
Granmo program (version 5.2).
Statistical analysis
Analyses were based on the intention-to-treat principle.
Initially, an analysis of baseline comparability of the
groups will be performed with respect to the variables
studied. The next phase will be the estimation of raw effect
on the outcome variables.
We will use multilevel analyses, with cluster as the ran-
dom intercept, because of the cluster randomization.
Baseline values of the dependent variable will be included
as covariates.
We will describe the evolution in health-related quality-
of-life (8 scales, and 2 composite measures) in partici-
pants over different time periods since quitting smoking.
The SPSS statistical package (version 15) and STATA (ver-
sion 10) are used throughout.
Quality control
Several procedures were employed to ensure the quality of
the study data, thus maximising validity and reliability of
the program delivery and outcome assessments. These are:
▪ Written documentation: printed and electronic copies of
protocols, session plans and consent forms stored at a
central site. All written documentation, including letters
sent to participants are standardized across sites and are
subject to local institutional ethics committee approval.
▪ Training: telephone interviewers were trained on charac-
teristics and procedures of the study in a 4 hours session.
▪ Regular meetings and mailings between members of the
study group (the ISTAPS team) and all participating cent-
ers.
▪ Evaluations of teaching sessions: facilitators evaluate the
extent of the planned content of each teaching session by
completing a standardized evaluation form. This ensures
the consistency of the program delivery at each site.
Ethical aspects
The study respects the Declaration of Helsinki and succes-
sive revisions, as well as the norms of good clinical prac-BMC Public Health 2009, 9:48 http://www.biomedcentral.com/1471-2458/9/48
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tice. The protocol has been studied and approved by the
CEIC – "Comité Ético de Investigación Clínica" (Clinical
Investigation Ethical Committee) of the "Institut d'Investi-
gació Primària Jordi Gol" [IDIAP-Jordi Gol].
Informed consent: The information was provided verbally
as well as in written form to all the participants. The indi-
viduals in the study had sufficient opportunity to ask
questions regarding the details of the study. The informed
consent form conforms to the norms of the Declaration of
Helsinki, and as stipulated in the Title I, Article 12 of the
(Spanish) Royal Decree 561/1993 of the 16th April, 1993.
Confidentiality of data: Only the investigators and moni-
tors/auditors of the study had access to the data of the sub-
jects who agreed to participate.
Discussion
The present study evaluates, under near real conditions,
the effectiveness in primary care of an overall strategy of
Time-line of the ISTAPS project Figure 1
Time-line of the ISTAPS project.
Prior procedures: Preparation of the definitive manual of 
procedures, data collection sheets, questionnaires, informed 
consent documents
Randomized assignment of basic units of care. 
Design and implementation of study-orientated courses for 
the health-care professionals in the intervention group
Start of the study: Control group and Intervention group
Instructions for telephone interviewers
Follow-up: 6 months
Follow-up: 1 year
Pre-
preparatory 
phase 
Follow-up: 2 years
Field-work BMC Public Health 2009, 9:48 http://www.biomedcentral.com/1471-2458/9/48
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Algorithm of the study Figure 2
Algorithm of the study.
Target population 
Persons t 14 years of age who, for 
whatever reason, consult  a family 
physician/nurse at a primary-care center 
(PCC) within a specific recruitment period, 
and who respond in the affirmative to the 
question: Do you smoke? 
Exclusion criteria: 
- Terminal illnesses 
- Severe psychiatric disorders 
- Addiction to other psycho-
active substances 
Informed consent 
ENTER STUDY 
Randomization by basic 
health-care unit (BHU)  
INTERVENTION
25 individuals/BHU 
CONTROL 
25 individuals/BHU 
Determine the stage-of-change 
Update the stage
Follow-up
6 months 
Measure CO, stage-of-
change, SF-36 
Training of health-care professionals Standard/normal care 
Follow-up  
6 months 
Measure CO, stage-of-
change, SF-36 
1st  year: 
Measure CO, stage-of-
change, SF-36 
2nd year: 
Measure CO, stage-of-
change, SF-36 
1st  year: 
Measure CO, stage-of-
change, SF-36 
2nd year: 
Measure CO, stage-of-
change, SF-36 BMC Public Health 2009, 9:48 http://www.biomedcentral.com/1471-2458/9/48
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smoking cessation, that includes specific interventions
addressed to people in all the stages-of-change. It is one of
the biggest studies ever undertaken, not only in primary
care but at all levels of clinical services. Given the almost
universal coverage of primary care in Spain, and consider-
ing that many people in the country belongs to social class
III to V, it is expected that the majority of the participants
of the study will belong to these social classes, generating
evidence of effectiveness in this type of population.
Another strength of the study is the large number of
health-care professionals and patients who are involved,
reinforcing the external validity of the data.
The theoretical framework used is the stages-of-change
model of Prochaska and Di Clemente. Despite the fact
that some authors such as West [33] or Riensma [12] have
questioned the utility of the model in the past years, it
remains as one of the most used conceptual frameworks.
Since one of the criticism made of the studies using the
model is the use of only one of the constructs (the stages
of change), in our study we make use of all of them:
stages, processes, self-efficacy and decisional balance; we
also validate our Spanish version in a complementary
study. Health-care professionals who volunteered to par-
ticipate in the present study could have been more moti-
vated than the health-care professionals working in other
PCCs. If this were to be the case, any resulting bias would
be in the direction of more conservative estimates of the
effects of the intervention. It has been decided to rand-
omize basic care unit instead of smokers as it would be
very difficult for a health-care professional (particularly
one who is well trained in applying a specific anti-smok-
ing intervention) to withhold this intervention in accord-
ance with the randomization procedure for specific
individuals; this would be especially true in the case of the
patient having certain pathologies related with smoking
or those who had tried to quit many times before, etc.
Given the feasibility of recruiting a considerable number
of basic care units in control and intervention groups, we
believe that this type of cluster randomized assignment is
necessary and we hope this will result in comparable
groups of basic care unit (health professionals) and
patients.
Although the unit of randomization is the basic care unit,
the intervention is given at the individual level and the
outcomes are also measured at this level. The estimation
of the design effect will be taken into acount in all the
main analysis.
The ISTAPS study is intended to be a pragmatic trial, trying
to develop an intervention that will be applied easily in
routine clinical practice. For this reason patients from 14
to 75 years coming to the practice for any reason were
included as it is unusual for patients in Spain to consult
specifically for smoking cessation advice; in many oca-
sions these patients presented with comorbidity.
One of the unique roles of primary care teams in smoking
cessation and control is to increase the motivation of
smokers to quit. In fact, in the many years which elapse
between the initiation of smoking (in Spain from 13 to 16
years old) until the beginning of smoking related diseases
or other causes of medical consultations, primary care are
the only services used by healthy and young or adult pop-
ulation. The ISTAPS study will include more than 60% of
their patients in the precontemplation and contemplation
stages (approx 1800) and that will allow us to study exten-
sively the effect of motivational interviewing in order to
enable an advance in the stage-of-change.
Since the practical clinical guidelines used in the present
study have not been yet disseminated, it will enable us to
perform the evaluation of the effectiveness using an exper-
imental study design. The guideline will not be available
until the end of 2008 and, as such, the study results will
not have been influenced by the widespread diffusion of
the guidelines.
The availability of health-related quality-of-life data ena-
bles us to evaluate the impact of quitting smoking on gen-
eral health, as well as on specific domains explored by the
SF-36 questionnaire. That will be of use when scheduling
visits of patients to primary care centres in the post-cessa-
tion period, so decreasing the possibility to relapse.
Conclusion
This study aims to demonstrate the effectiveness of a
smoking cessation intervention at the two year post-inter-
vention follow-up. The results will be useful to primary
care health professionals in their daily practice.
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(both behavioural and pharmacological) and, as such, to establish a molec-
ular basis for future therapies designed for each individual's requirements.
￿ Perception of risk of cancer in smokers: ISTAPS project 
(PRICA-ISTAPS)
Objectives: To evaluate the perception of cancer risk in smokers in a multi-
centred intervention study on the consumption of tobacco.
To compare the perception of cancer risk in smokers who remain tobacco 
free at the end of the follow-up with those who continue smoking.
To analyze the relationship between the effectiveness of intervention and 
the perceived risk at the start of the intervention
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